Premium
Biomarker and cytologic abnormalities in women at high and low risk for breast cancer
Author(s) -
Fabian Carol J.,
Zalles Carola,
Kamel Sahar,
McKittrick Richard,
Moore William P.,
Zeiger Sandy,
Simon Connie,
Kimler Bruce,
Cramer Ann,
Garcia Fernando,
Jewell William
Publication year - 1993
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240531129
Subject(s) - medicine , breast cancer , biomarker , dysplasia , atypical hyperplasia , breast disease , estrogen receptor , aneuploidy , pathology , cancer , hyperplasia , cytology , biopsy , risk factor , oncology , gastroenterology , gynecology , biology , biochemistry , gene , chromosome
Fine needle aspirates (FNA) from 106 high‐risk women and 25 low‐risk women were evaluated for overexpression of estrogen receptor (ER), epidermal growth factor receptor (EGFR), mutant p53, and HER‐2/ neu by immunocytochemistry, and for aneuploidy by image analysis. Aspirates were also classified cytologically as normal, apocrine metaplasia, epithelial hyperplasia (EH), or dysplasia. High‐risk women were those with a first‐degree relative with breast cancer (76%), precancerous breast disease (26%), prior cancer of the contralateral breast (9%), or multiple abnormalities (11%). Low‐risk women had none of the above risk factors, nor a prior breast biopsy or clinical evidence of fibrocystic disease. The median 10‐year Gail risk for the high‐risk group was 4%, compared to 0.7% for the low‐risk group. There were significant differences (p < 0.01) between high‐ and low‐risk women in the prevalences of hyperplasia (55% versus 12%), dysplasia (19% versus 0%), aneuploidy (32% versus 0%), overexpressed EGFR (32% versus 4%), and overexpressed p53 (29% versus 4%). The prevalence of multiple biomarker abnormalities was also greater in high‐risk than in low‐risk women (28% versus 0%; p < 0.01). Four percent (4%) of FNAs from high‐risk women with normal cytology, 29% of aspirates with hyperplastic cytology, and 60% of those with dysplasia were associated with two or more biomarker abnormalities. The differences in the prevalence of multiple biomarker abnormalities among various cytologic categories were statistically significant (p = 0.02, normal versus EH; p = 0.02, EH versus dysplasia; p < 0.01, normal versus dysplasia). Further study of these tissue biomarkers as potential intermediate‐term (5–10 year) predictors of breast cancer development is warranted.